JP2010516639A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516639A5 JP2010516639A5 JP2009545828A JP2009545828A JP2010516639A5 JP 2010516639 A5 JP2010516639 A5 JP 2010516639A5 JP 2009545828 A JP2009545828 A JP 2009545828A JP 2009545828 A JP2009545828 A JP 2009545828A JP 2010516639 A5 JP2010516639 A5 JP 2010516639A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- carcinoma
- tumor
- sarcoma
- gland
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000011510 cancer Diseases 0.000 claims description 19
- 201000009030 carcinoma Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 7
- 208000009956 Adenocarcinoma Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000004064 Acoustic Neuroma Diseases 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000006990 Cholangiocarcinoma Diseases 0.000 claims description 3
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 3
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 3
- 208000002445 Cystadenocarcinoma Diseases 0.000 claims description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 3
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 3
- 206010024190 Leiomyosarcomas Diseases 0.000 claims description 3
- 206010024324 Leukaemias Diseases 0.000 claims description 3
- 206010024627 Liposarcoma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 206010027191 Meningioma Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 206010025310 Other lymphomas Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 3
- 210000004560 Pineal Gland Anatomy 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 210000001732 Sebaceous Glands Anatomy 0.000 claims description 3
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims description 3
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 claims description 3
- 208000008383 Wilms Tumor Diseases 0.000 claims description 3
- 201000003076 angiosarcoma Diseases 0.000 claims description 3
- 201000006491 bone marrow cancer Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000009047 chordoma Diseases 0.000 claims description 3
- 201000008808 fibrosarcoma Diseases 0.000 claims description 3
- 201000002222 hemangioblastoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 201000009251 multiple myeloma Diseases 0.000 claims description 3
- 201000008026 nephroblastoma Diseases 0.000 claims description 3
- 201000010133 oligodendroglioma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 201000010208 seminoma Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 230000002861 ventricular Effects 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 210000004907 Glands Anatomy 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 2
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 2
- 201000000582 retinoblastoma Diseases 0.000 claims description 2
- 230000003511 endothelial Effects 0.000 claims 2
- 230000001926 lymphatic Effects 0.000 claims 2
- 210000000981 Epithelium Anatomy 0.000 claims 1
- 210000003097 Mucus Anatomy 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 201000010965 sweat gland carcinoma Diseases 0.000 claims 1
- 101710023137 HSP90B1 Proteins 0.000 description 4
- 101700017615 HSP82 Proteins 0.000 description 3
- 101700042119 HSP83 Proteins 0.000 description 3
- 101710006465 MOD-E Proteins 0.000 description 3
- 210000003038 Endothelium Anatomy 0.000 description 2
- 206010025224 Lymphangiosarcomas Diseases 0.000 description 2
- 206010025650 Malignant melanoma Diseases 0.000 description 2
- 208000001611 Myxosarcoma Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001605 fetal Effects 0.000 description 2
- 201000008064 heavy chain disease Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 201000008759 sweat gland cancer Diseases 0.000 description 2
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 210000001130 Astrocytes Anatomy 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 208000003362 Bronchogenic Carcinoma Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 206010007963 Central nervous system vascular disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100009909 HSP90B1 Human genes 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OSSPJABMWOOUGD-UHFFFAOYSA-N N-butyl-6-hydroxy-N-methyl-3-[4-(2-methylphenyl)-5-oxo-1,2,4-triazolidin-3-ylidene]-4-oxocyclohexa-1,5-diene-1-carboxamide Chemical compound O=C1C=C(O)C(C(=O)N(C)CCCC)=CC1=C1N(C=2C(=CC=CC=2)C)C(=O)NN1 OSSPJABMWOOUGD-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000004019 Papillary Adenocarcinoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000008864 Scrapie Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Description
本発明はまた、本発明による化合物の、化学療法による毒性から正常細胞を保護するための使用に、および、タンパク質の誤った折りたたみまたは凝集が主要な原因因子である疾患、例えば、スクレイピー、クロイツフェルト−ヤコブ病、ハンチントン病またはアルツハイマー病(Sittler, Hum. Mol. Genet., 10, 1307, 2001;Tratzelt et al., Proc. Nat. Acad. Sci., 92, 2944, 1995;Winklhofer et al., J. Biol. Chem., 276, 45160, 2001)における使用に関する。
A. Kamal et al.によるTrends in Molecular Medicine, Vol. 10 No. 6 June 2004には、HSP90活性化の、特に中枢神経系の疾患および循環器疾患の処置のための、治療的および診断的用途が記載されている。
したがって、HSP90を特異的に阻害、調節および/または調整する小化合物の同定は望ましく、本発明の目的である。
宿主または患者は、任意の哺乳類種に属してよく、例えば、霊長類種、特にヒト;マウス、ラットおよびハムスターを含むげっ歯類;ウサギ、ウマ、ウシ、イヌ、ネコなどである。動物モデルは、実験的研究において興味深く、ここで動物モデルはヒト疾患の処置のためのモデルを提供する。
WO 01/72779には、プリン化合物およびその使用であって、GRP94(HSP90の相同体またはパラログ)誘発性の疾患、例えば腫瘍疾患などの、癌組織が以下からから選択される肉腫または癌腫を含むものの処置のための、前記使用について記載されている:線維肉腫、粘液肉腫、脂肪肉腫、軟骨肉腫、骨肉腫、脊索腫、血管肉腫、内皮肉腫、リンパ管肉腫、リンパ管内皮肉腫、滑膜腫、中皮腫、ユーイング腫瘍、平滑筋肉腫、横紋筋肉腫、大腸癌、膵臓癌、乳癌、卵巣癌、前立腺癌、扁平上皮癌、基底細胞癌、腺癌、汗腺癌、皮脂腺癌、乳頭状癌、乳頭状腺癌、嚢胞腺癌、骨髄癌、気管支原生癌、腎細胞癌、肝細胞癌、胆管癌、絨毛癌、精上皮腫、胎生期癌、ウィルムス腫瘍、頸部癌、精巣腫瘍、肺癌、小細胞肺癌、膀胱癌、上皮癌、神経膠腫、星状細胞腫、髄芽細胞腫、頭蓋咽頭腫、脳室上衣細胞腫、松果体腫、血管芽細胞腫、聴神経腫、乏突起神経膠腫、髄膜腫、黒色腫、神経芽細胞腫、網膜芽細胞腫、白血病、リンパ腫、多発性骨髄腫、ワルデンストレームマクログロブリン血症、およびH鎖病。
本発明は、5−[4−(2−メチルフェニル)−3−ヒドロキシ−4H−1,2,4−トリアゾール−5−イル]−2,4−ジヒドロキシ−N−メチル−N−ブチルベンズアミド、およびその薬学的に使用し得る誘導体、溶媒和物および立体異性体、ならびにそれらの全ての比率での混合物の使用であって、以下の疾患の処置のための、医薬の製造のための前記使用を包含する:腫瘍疾患、例えば、線維肉腫、粘液肉腫、脂肪肉腫、軟骨肉腫、骨肉腫、脊索腫、血管肉腫、内皮肉腫、リンパ管肉腫、リンパ管内皮肉腫、滑膜腫、中皮腫、ユーイング腫瘍、平滑筋肉腫、横紋筋肉腫、大腸癌、膵臓癌、乳癌、卵巣癌、前立腺癌、扁平上皮癌、基底細胞癌、腺癌、汗腺癌、皮脂腺癌、乳頭状癌、乳頭状腺癌、嚢胞腺癌、骨髄癌、気管支原生癌、腎細胞癌、肝細胞癌、胆管癌、絨毛癌、精上皮腫、胎生期癌、ウィルムス腫瘍、頸部癌、精巣腫瘍、肺癌、小細胞肺癌、膀胱癌、上皮癌、神経膠腫、星状細胞腫、髄芽細胞腫、頭蓋咽頭腫、脳室上衣細胞腫、松果体腫、血管芽細胞腫、聴神経腫、乏突起神経膠腫、髄膜腫、黒色腫、神経芽細胞腫、網膜芽細胞腫、白血病、リンパ腫、多発性骨髄腫、ワルデンストレームマクログロブリン血症、およびH鎖病;
Claims (1)
- 腫瘍疾患が、線維肉腫、粘液肉腫、脂肪肉腫、軟骨肉腫、骨肉腫、脊索腫、血管肉腫、内皮肉腫、リンパ管肉腫、リンパ管内皮肉腫、滑膜腫、中皮腫、ユーイング腫瘍、平滑筋肉腫、横紋筋肉腫、大腸癌、膵臓癌、乳癌、卵巣癌、前立腺癌、扁平上皮癌、基底細胞癌、腺癌、汗腺癌、皮脂腺癌、乳頭状癌、乳頭状腺癌、嚢胞腺癌、骨髄癌、気管支原生癌、腎細胞癌、肝細胞癌、胆管癌、絨毛癌、精上皮腫、胎生期癌、ウィルムス腫瘍、頸部癌、精巣腫瘍、肺癌、小細胞肺癌、膀胱癌、上皮癌、神経膠腫、星状細胞腫、髄芽細胞腫、頭蓋咽頭腫、脳室上衣細胞腫、松果体腫、血管芽細胞腫、聴神経腫、乏突起神経膠腫、髄膜腫、黒色腫、神経芽細胞腫、網膜芽細胞腫、白血病、リンパ腫、多発性骨髄腫、ワルデンストレームマクログロブリン血症、およびH鎖病である、請求項5に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007002715A DE102007002715A1 (de) | 2007-01-18 | 2007-01-18 | Triazolderivat |
DE102007002715.1 | 2007-01-18 | ||
PCT/EP2007/010775 WO2008086857A1 (de) | 2007-01-18 | 2007-12-11 | Triazolderivat als hsp 90 inhibitor |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010516639A JP2010516639A (ja) | 2010-05-20 |
JP2010516639A5 true JP2010516639A5 (ja) | 2011-02-03 |
JP5266253B2 JP5266253B2 (ja) | 2013-08-21 |
Family
ID=39345628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009545828A Expired - Fee Related JP5266253B2 (ja) | 2007-01-18 | 2007-12-11 | Hsp90阻害剤としてのトリアゾール誘導体 |
Country Status (22)
Country | Link |
---|---|
US (1) | US8816070B2 (ja) |
EP (1) | EP2102175B1 (ja) |
JP (1) | JP5266253B2 (ja) |
KR (1) | KR20090101381A (ja) |
CN (1) | CN101583605B (ja) |
AR (1) | AR064951A1 (ja) |
AU (1) | AU2007344512B2 (ja) |
BR (1) | BRPI0720956A2 (ja) |
CA (1) | CA2675737C (ja) |
CL (1) | CL2008000134A1 (ja) |
DE (1) | DE102007002715A1 (ja) |
EA (1) | EA015366B1 (ja) |
EC (1) | ECSP099586A (ja) |
ES (1) | ES2455504T3 (ja) |
MX (1) | MX2009007479A (ja) |
MY (1) | MY151452A (ja) |
NZ (1) | NZ579069A (ja) |
PE (1) | PE20090051A1 (ja) |
TW (1) | TW200838502A (ja) |
UA (1) | UA98320C2 (ja) |
WO (1) | WO2008086857A1 (ja) |
ZA (1) | ZA200905700B (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008287367B2 (en) * | 2007-08-13 | 2012-02-23 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
SI2490688T1 (sl) * | 2009-10-19 | 2015-01-30 | Synta Pharmaceuticals Corp. | Kombinirano zdravljenje raka s spojinami - zaviralci HSP90 |
US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
DE102010024338A1 (de) | 2010-06-18 | 2011-12-22 | Merck Patent Gmbh | Verfahren zur Herstellung von 5-[4-(2-Methyl-phenyl)-3-hydroxy-4H-[1,2,4]triazol-5-yl]-2,4-dihydroxy-methyl-butyl-benzamid |
RS54112B1 (en) * | 2010-10-01 | 2015-12-31 | Taisho Pharmaceutical Co. Ltd | DERIVAT 1,2,4-TRIAZOLONA |
US20130338178A1 (en) * | 2011-02-02 | 2013-12-19 | The Trustees Of Princeton University | Sirtuin modulators as inhibitors of cytomegalovirus |
WO2013067162A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
WO2013067165A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
EP2780010A1 (en) | 2011-11-14 | 2014-09-24 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
CN106478531B (zh) * | 2015-08-25 | 2019-06-28 | 南京华威医药科技集团有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸中间体 |
IL278698B2 (en) * | 2018-05-14 | 2024-06-01 | Reata Pharmaceuticals Inc | Bi-aryl amides with sugar groups that are adapted to the treatment of diseases related to the heat stroke protein pathway |
CN115006395B (zh) * | 2022-04-29 | 2023-03-14 | 佛山病原微生物研究院 | 一种xl888在制备用于抗腺病毒感染的药物中的用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
WO1999051223A1 (en) | 1998-04-03 | 1999-10-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
EP1161231A2 (en) | 1999-03-12 | 2001-12-12 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH | Method of inhibiting a chaperone protein |
AU2001247759A1 (en) | 2000-03-24 | 2001-10-08 | Duke University | Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
US6887853B2 (en) | 2000-06-29 | 2005-05-03 | The Trustees Of Boston University | Use of geldanamycin and related compounds for treatment of fibrogenic disorders |
JP2004504356A (ja) | 2000-07-20 | 2004-02-12 | メルク エンド カムパニー インコーポレーテッド | C型肝炎ウイルスのプロセシングおよび複製の抑制 |
WO2002009696A1 (en) | 2000-07-28 | 2002-02-07 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
CN1501928A (zh) | 2000-11-02 | 2004-06-02 | 斯隆-凯特林癌症研究所 | 结合hsp90的小分子组合物 |
WO2003041643A2 (en) | 2001-11-09 | 2003-05-22 | Conforma Therapeutics Corporation | Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
JP4399265B2 (ja) | 2001-12-21 | 2010-01-13 | ヴァーナリス(ケンブリッジ)リミテッド | 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
US7691838B2 (en) | 2003-05-30 | 2010-04-06 | Kosan Biosciences Incorporated | Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics |
US20050020556A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
US20050020534A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
US20050054589A1 (en) | 2003-05-30 | 2005-03-10 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics |
US20050054625A1 (en) | 2003-05-30 | 2005-03-10 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors |
US20050026893A1 (en) | 2003-05-30 | 2005-02-03 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants |
US20050020557A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors |
CN103554042B (zh) * | 2004-11-18 | 2016-08-10 | Synta医药公司 | 调节hsp90活性的三唑化合物 |
DE102005007304A1 (de) | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
-
2007
- 2007-01-18 DE DE102007002715A patent/DE102007002715A1/de not_active Withdrawn
- 2007-12-11 CA CA2675737A patent/CA2675737C/en active Active
- 2007-12-11 MX MX2009007479A patent/MX2009007479A/es active IP Right Grant
- 2007-12-11 MY MYPI20092959 patent/MY151452A/en unknown
- 2007-12-11 EP EP07856537.1A patent/EP2102175B1/de active Active
- 2007-12-11 US US12/523,387 patent/US8816070B2/en active Active
- 2007-12-11 ES ES07856537.1T patent/ES2455504T3/es active Active
- 2007-12-11 NZ NZ579069A patent/NZ579069A/en not_active IP Right Cessation
- 2007-12-11 JP JP2009545828A patent/JP5266253B2/ja not_active Expired - Fee Related
- 2007-12-11 KR KR1020097016991A patent/KR20090101381A/ko not_active Application Discontinuation
- 2007-12-11 WO PCT/EP2007/010775 patent/WO2008086857A1/de active Application Filing
- 2007-12-11 EA EA200900913A patent/EA015366B1/ru not_active IP Right Cessation
- 2007-12-11 CN CN2007800499639A patent/CN101583605B/zh active Active
- 2007-12-11 AU AU2007344512A patent/AU2007344512B2/en not_active Ceased
- 2007-12-11 UA UAA200908637A patent/UA98320C2/ru unknown
- 2007-12-11 BR BRPI0720956-8A patent/BRPI0720956A2/pt not_active IP Right Cessation
-
2008
- 2008-01-16 CL CL200800134A patent/CL2008000134A1/es unknown
- 2008-01-17 TW TW097101845A patent/TW200838502A/zh unknown
- 2008-01-17 PE PE2008000150A patent/PE20090051A1/es not_active Application Discontinuation
- 2008-01-18 AR ARP080100223A patent/AR064951A1/es unknown
-
2009
- 2009-08-17 ZA ZA200905700A patent/ZA200905700B/xx unknown
- 2009-08-17 EC EC2009009586A patent/ECSP099586A/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010516639A5 (ja) | ||
JP2010533132A5 (ja) | ||
Sun et al. | Natural berberine-hybridized benzimidazoles as novel unique bactericides against Staphylococcus aureus | |
Dheer et al. | Medicinal attributes of 1, 2, 3-triazoles: Current developments | |
Shafiei et al. | History of the development of antifungal azoles: A review on structures, SAR, and mechanism of action | |
Karakurt et al. | Synthesis, anticonvulsant and antimicrobial activities of some new 2-acetylnaphthalene derivatives | |
Singh et al. | New coumarin-benzotriazole based hybrid molecules as inhibitors of acetylcholinesterase and amyloid aggregation | |
BRPI0510206A (pt) | método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação | |
NO20054769D0 (no) | Substituerte fenylalkansyrer | |
WO2007130383A3 (en) | Compositions and treatments using pyridazine compounds and secretases | |
BR0311291A (pt) | Derivados de aminoindazol ativos como inibidores da cinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos | |
MA29462B1 (fr) | Imidazoquinolines utilises en tant qu'inhibiteurs de kinase lipidique | |
JP2018534301A (ja) | 新規ガラクトシドによるガレクチン阻害剤 | |
Gupta et al. | Destabilization potential of phenolics on Aβ fibrils: Mechanistic insights from molecular dynamics simulation | |
EA200300514A1 (ru) | Фармацевтические композиции агониста nmda-рецепторов | |
CN102333752A (zh) | 氧杂二环庚烷与氧杂二环庚烯、它们的制备及应用 | |
Łączkowski et al. | Thiazoles with cyclopropyl fragment as antifungal, anticonvulsant, and anti-Toxoplasma gondii agents: synthesis, toxicity evaluation, and molecular docking study | |
NO20065717L (no) | Substituerte N-arylbenzamider og beslektede forbindelser for behandling av amyloidsykdommer og synukleinopatier. | |
Ahsan et al. | Pyrazoline containing compounds as therapeutic targets for neurodegenerative disorders | |
TW200613281A (en) | Propane-1,3-dione derivative or salt thereof | |
Faião-Flores et al. | DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1, 4-dienyl]-2-methoxy-phenolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment | |
JP5759000B2 (ja) | 肝疾患治療の薬物の製造におけるジインドリルメタン及びその前駆体並びにその誘導体の応用 | |
Ozdemir et al. | Synthesis, anticonvulsant and antimicrobial activities of some new [1-(2-naphthyl)-2-(pyrazol-1-yl) ethanone] oxime ethers | |
Brahmbhatt et al. | Synthesis, characterization, antibacterial and antioxidant potency of N-substituted-2-sulfanylidene-1, 3-thiazolidin-4-one derivatives and QSAR study | |
Ye et al. | Actively targeted delivery of doxorubicin to bone metastases by a pH-sensitive conjugation |